News Headlines

  1. Recipharm Strengthens Brand To Reinforce Customer Focus And Manufacturing Leadership 9/2/2025

    Recipharm, a leading global contract development and manufacturing organisation (CDMO), today unveiled a refreshed brand strategy that showcases the breadth and depth of its capabilities, and reinforces the company's ongoing commitment to delivering quality, reliability and value for its customers worldwide.

  2. OMass Therapeutics Enters Into Exclusive Collaboration And License Agreement With Genentech To Develop And Commercialize Therapies For Inflammatory Bowel Disease 9/2/2025

    OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that it has entered into an exclusive collaboration and license agreement with Genentech, a member of the Roche Group, for the rights to develop and commercialize OMass’ preclinical oral small molecule program for inflammatory bowel disease.

  3. Quotient Sciences And CPI To Accelerate RNA Drug Development With Joint Venture 9/2/2025

    Quotient Sciences announced a new partnership with the UK CPI (Centre for Process Innovation) to help accelerate mRNA therapeutics — combining CPI capabilities in LNP manufacturing and technology with Quotient Sciences' clinical and drug product development platform, Translational Pharmaceutics®.

  4. eXmoor Pharma And Anthony Nolan Cell Therapy And Laboratory Services To Offer End-To-End Support For Cell Therapy Developers 9/2/2025

    eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, has announced a new strategic partnership with Anthony Nolan: Cell Therapy & Laboratory Services (CT&LS), the experts in cellular starting materials providing donor material solutions to the cell and gene therapy industry.

  5. Naobios, Nuvonis And European Vaccine Initiative Collaborate On Manufacturing Influenza Challenge Agent 9/2/2025

    Naobios, a CDMO providing bioprocess development and good manufacturing practices (GMP) production of clinical batches of virus-based products, Nuvonis, a biotechnological company providing innovative cell banks for the production of vaccines and other biologicals, and the European Vaccine Initiative (EVI), a leading European non-profit Product Development Partnership (PDP), today announce a joint effort through the Inno4Vac consortium to develop an influenza A(H3N2) Human Viral Challenge Agent with the long-term goal of addressing the low effectiveness of seasonal influenza vaccines in fighting influenza A(H3N2).

  6. Thermo Fisher Scientific Completes Acquisition Of Sanofi's Ridgefield, New Jersey Site 9/2/2025

    Thermo Fisher Scientific Inc., the world leader in serving science, today announced the completion of its acquisition of Sanofi’s state-of-the-art sterile fill-finish and packaging site in Ridgefield, New Jersey, marking an expansion of the companies’ strategic partnership to enable additional U.S. drug product manufacturing.

  7. LOTTE BIOLOGICS Establishes Contract Manufacturing Partnership With A Leading U.S. Biopharmaceutical Company 9/1/2025

    LOTTE BIOLOGICS (CEO James Park) today announced that it has entered a late-stage to commercial contract manufacturing partnership with a U.S.-based global biopharmaceutical company.

  8. Accro Bioscience And Fosun Pharma Announce Exclusive License Agreement For AC-201, A Highly Selective TYK2/JAK1 Inhibitor In Greater China 8/29/2025

    Accro Bioscience and Fosun Pharma today announced that Accro will grant exclusive rights to develop, manufacture, and commercialize its independently developed, highly selective TYK2/JAK1 inhibitor to Fosun Pharma in Greater China (including Chinese Mainland, Hong Kong SAR, and Macau SAR).

  9. Indena And TCG GreenChem Join Forces To Advance Next-Generation ADC Technologies 8/28/2025

    Indena and TCG GreenChem are pleased to announce a new strategic collaboration aimed at accelerating the development of innovative and market-ready payload-linkers, the key component of Antibody-Drug Conjugates (ADCs).

  10. Sai Life Sciences Completes Phase II Of Production Block 11 At Bidar Site, India, Expands Capacity To 700 KL 8/28/2025

    Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV).